Protection against MERS-CoV infection by immunization with genetically engineered live-attenuated viruses
Protection against MERS-CoV infection by immunization with genetically engineered live-attenuated viruses
Middle East respiratory syndrome coronavirus (MERS-CoV) is a life threatening human coronavirus, against which there are no approved treatments or vaccines. Our laboratory has engineered two types of live-attenuated vaccine candidates. The first one is based on the full deletion of the envelope (E) protein (rMERS-CoV-deltaE), which resulted in a replication-competent and propagation-defective one-cycle virus (RcPd). The second type, a replication-competent and propagation-competent virus (RcPc), initially consisted of a collection of six rMERS- CoVs carrying partial deletions of 9-11 amino acids spanning the C-terminal domain of the E protein (rMERS- CoV-E*).
Trabajo presentado en el XIV International Nidovirus Symposium 2017, celebrado en Kansas City, Missouri (Estados Unidos), del 4 al 9 de junio de 2017
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!